Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ADI-PEG 20 + Cabazitaxel + Carboplatin |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ADI-PEG 20 | Pegargiminase|ADI-PEG20|pegylated arginine deiminase | Pegargiminase (ADI-PEG 20) is polyethylene glycol-conjugated arginine deiminase which degrades arginine, thereby depleting arginine and potentially inhibiting growth of arginine-dependent tumor cells (PMID: 22864522, PMID: 30796035, PMID: 32409304). | ||
Cabazitaxel | Jevtana | XRP6258|RPR-116258A | Antimicrotubule Agent 14 | Jevtana (cabazitaxel) inhibits microtubule depolymerization by binding to tubulin, resulting in cell cycle arrest and decreased tumor cell proliferation (PMID: 32660451). |
Carboplatin | Paraplatin | CBDCA | Chemotherapy - Platinum 7 | Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|